NEW YORK (GenomeWeb News) – Translational life science tools and molecular diagnostics company NanoString Technologies today filed for an initial public offering.

In its Form S-1 filed with the US Securities and Exchange Commission, the Seattle-based company said it anticipates a proposed maximum aggregate offering price of about $86.3 million, but did not provide a price range for its shares or the amount of shares to be sold.

JP Morgan and Morgan Stanley will be joint book-running managers for the offering, and Leerink Swann and R.W. Baird will act as co-managers.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: Icelandic genome sequences, approach to increase CRISPR efficiency, and more.

Testing showing "genetic incompatibilities" have led thousands of couples in Saudi Arabia to call off their weddings, the BBC reports.

Decode Genetics' ability to tell Icelanders, even ones the company hasn't sequenced, about their disease risk brings up ethical questions.

Genetic analysis of Britain's King Richard III and modern descendants of his relatives indicate breaks in the male line.